AstraZeneca PLC (NASDAQ:AZN) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET

Corporate Participants

Andy Barnett - Head, Investor Relations

Pascal Soriot - Chief Executive Officer

Aradhana Sarin - Chief Financial Officer

David Fredrickson - EVP, Oncology Business

Susan Galbraith - EVP, Oncology R&D

Ruud Dobber - EVP, BioPharmaceuticals Business

Sharon Barr - EVP, BioPharmaceuticals R&D

Marc Dunoyer - Chief Executive Officer, Alexion

Conference Call Participants

Steve Scala - Cowen

Gonzalo Artiach - ABG

Andrew Baum - Citi

Sachin Jain - Bank of America

Tim Anderson - Bernstein

Emily Field - Barclays

James Gordon - JPMorgan

Mattias Häggblom - Handelsbanken

Mark Purcell - Morgan Stanley

Eric Le Berrigaud - Stifel

Richard Parkes - BNP

Christopher Uhde - SEB

Simon Baker - Redburn

Luisa Hector - Berenberg

Emmanuel Papadakis - Deutsche Bank

Peter Welford - Jefferies

Operator

Good morning to those joining from the U.S. Good afternoon to those in the U.K. and Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen to AstraZeneca's Nine Months and Q3 Results 2023 Conference Call and Webinar for Investors and Analysts.

Before I hand over to AstraZeneca, I'd like to read the Safe Harbor statement. The company intends to utilize the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties, and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking

Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking statements.

Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation and webinar.

There will be an opportunity to ask questions after today's presentations. Please use the raise a hand feature to indicate your wish to ask a question and remember to unmute your line when invited to speak.

And with that, I will now hand you over to the company.

Andy Barnett

Thank you, operator. I'm Andy Barnett, Head of Investor Relations at AstraZeneca and I'm very pleased to welcome you to AstraZeneca's nine months and third quarter of 2023 conference call.